37700152|t|Gys1 Antisense Therapy Prevents Disease-Driving Aggregates and Epileptiform Discharges in a Lafora Disease Mouse Model.
37700152|a|Patients with Lafora disease have a mutation in EPM2A or EPM2B, resulting in dysregulation of glycogen metabolism throughout the body and aberrant glycogen molecules that aggregate into Lafora bodies. Lafora bodies are particularly damaging in the brain, where the aggregation drives seizures with increasing severity and frequency, coupled with neurodegeneration. Previous work employed mouse genetic models to reduce glycogen synthesis by approximately 50%, and this strategy significantly reduced Lafora body formation and disease phenotypes. Therefore, an antisense oligonucleotide (ASO) was developed to reduce glycogen synthesis in the brain by targeting glycogen synthase 1 (Gys1). To test the distribution and efficacy of this drug, the Gys1-ASO was administered to Epm2b-/- mice via intracerebroventricular administration at 4, 7, and 10 months. The mice were then sacrificed at 13 months and their brains analyzed for Gys1 expression, glycogen aggregation, and neuronal excitability. The mice treated with Gys1-ASO exhibited decreased Gys1 protein levels, decreased glycogen aggregation, and reduced epileptiform discharges compared to untreated Epm2b-/- mice. This work provides proof of concept that a Gys1-ASO halts disease progression of EPM2B mutations of Lafora disease.
37700152	63	86	Epileptiform Discharges	Disease	MESH:D019522
37700152	92	106	Lafora Disease	Disease	MESH:D020192
37700152	134	148	Lafora disease	Disease	MESH:D020192
37700152	168	173	EPM2A	Gene	7957
37700152	177	182	EPM2B	Gene	378884
37700152	214	222	glycogen	Chemical	MESH:D006003
37700152	267	275	glycogen	Chemical	MESH:D006003
37700152	306	319	Lafora bodies	Disease	MESH:D020192
37700152	321	334	Lafora bodies	Disease	MESH:D020192
37700152	404	412	seizures	Disease	MESH:D012640
37700152	466	483	neurodegeneration	Disease	MESH:D019636
37700152	539	547	glycogen	Chemical	MESH:D006003
37700152	620	626	Lafora	Disease	MESH:D020192
37700152	690	705	oligonucleotide	Chemical	MESH:D009841
37700152	736	744	glycogen	Chemical	MESH:D006003
37700152	781	800	glycogen synthase 1	Gene	14936
37700152	802	806	Gys1	Gene	14936
37700152	865	869	Gys1	Gene	14936
37700152	894	899	Epm2b	Gene	105193
37700152	1048	1052	Gys1	Gene	14936
37700152	1065	1073	glycogen	Chemical	MESH:D006003
37700152	1136	1140	Gys1	Gene	14936
37700152	1165	1169	Gys1	Gene	14936
37700152	1196	1204	glycogen	Chemical	MESH:D006003
37700152	1230	1253	epileptiform discharges	Disease	MESH:D019522
37700152	1276	1281	Epm2b	Gene	105193
37700152	1334	1338	Gys1	Gene	14936
37700152	1372	1377	EPM2B	Gene	378884
37700152	1391	1405	Lafora disease	Disease	MESH:D020192
37700152	Association	MESH:D020192	105193
37700152	Association	MESH:D020192	378884
37700152	Association	MESH:D006003	7957
37700152	Association	MESH:D006003	378884
37700152	Negative_Correlation	MESH:D006003	14936
37700152	Association	MESH:D019522	14936
37700152	Negative_Correlation	MESH:D009841	14936
37700152	Association	MESH:D020192	7957
37700152	Positive_Correlation	MESH:D006003	MESH:D020192
37700152	Association	MESH:D020192	14936

